The Clinical Implication of Tumoral Gal-1 Expression in Laryngeal Squamous Cell Carcinomas

Overview

Journal Clin Transl Oncol

Specialty Oncology

Date 2013 Jan 30

PMID 23359172

Citations 1

Authors

J Ye

H Liu

Y Hu

G Wan

J Li

Z Wang

P Li

G Zhang

Y Li

Affiliations

Soon will be listed here.

Abstract

Purpose: To explore the expression of tumoral Gal-1 in association with clinical parameters and outcome in a large population with laryngeal squamous cell carcinomas (LSCCs).

Methods: A total of 187 patients with LSCC were retrospectively enrolled. Immunohistochemistry was performed to evaluate the tumoral expression of Gal-1, apoptosis-related proteins and the density of tumor infiltrating lymphocytes (TILs) in tumor tissues before any intervene. Survival curves were estimated by the Kaplan-Meier method, and differences in survival between groups were determined using the log-rank test. Prognostic effects were evaluated by Cox regression analysis.

Results: A total of 102 carcinomas (54.5 %) were identified as high Gal-1 expression, and 85 carcinomas (45.5 %) as low expression. Tumoral Gal-1 expression was not significantly related with clinical stage and histology differentiation. No correlation of Gal-1 expression with apoptosis-related protein was identified. Instead, Gal-1 status was correlated positively with the ratio of FOXP3(+)/CD8(+) TILs (P = 0.024). In multivariate regression analysis, advanced clinical stage and the presence of metastases were identified as the independent predictors for poor survival in entire cohort. Especially, the statistical correlation between the Gal-1 expression and prognosis was particularly due to the late-stage tumors (P < 0.05).

Conclusion: Current results represent valuable advancements in Gal-1 research and provided further support for using Gal-1 as a diagnostic biomarker and immunotherapeutic target for LSCC.

Citing Articles

Prognostic significance of galectin-1 expression in patients with cancer: a meta-analysis.

Wu R, Wu T, Wang K, Luo S, Chen Z, Fan M Cancer Cell Int. 2018; 18:108.

PMID: 30087582 PMC: 6076397. DOI: 10.1186/s12935-018-0607-y.

References

Chiang W, Liu S, Fang L, Lin C, Wu M, Chen Y . Overexpression of galectin-1 at the tumor invasion front is associated with poor prognosis in early-stage oral squamous cell carcinoma. Oral Oncol. 2007; 44(4):325-34. DOI: 10.1016/j.oraloncology.2007.03.004. View

Juszczynski P, Ouyang J, Monti S, Rodig S, Takeyama K, Abramson J . The AP1-dependent secretion of galectin-1 by Reed Sternberg cells fosters immune privilege in classical Hodgkin lymphoma. Proc Natl Acad Sci U S A. 2007; 104(32):13134-9. PMC: 1936978. DOI: 10.1073/pnas.0706017104. View

Le Q, Shi G, Cao H, Nelson D, Wang Y, Chen E . Galectin-1: a link between tumor hypoxia and tumor immune privilege. J Clin Oncol. 2005; 23(35):8932-41. DOI: 10.1200/JCO.2005.02.0206. View

Liu H, Zhang T, Ye J, Li H, Huang J, Li X . Tumor-infiltrating lymphocytes predict response to chemotherapy in patients with advance non-small cell lung cancer. Cancer Immunol Immunother. 2012; 61(10):1849-56. PMC: 11029471. DOI: 10.1007/s00262-012-1231-7. View

Allen C, Judd N, Bui J, Uppaluri R . The clinical implications of antitumor immunity in head and neck cancer. Laryngoscope. 2011; 122(1):144-57. DOI: 10.1002/lary.21913. View

Salatino M, Croci D, Bianco G, Ilarregui J, Toscano M, Rabinovich G . Galectin-1 as a potential therapeutic target in autoimmune disorders and cancer. Expert Opin Biol Ther. 2007; 8(1):45-57. DOI: 10.1517/14712598.8.1.45. View

Bektas S, Bahadir B, Ucan B, Ozdamar S . CD24 and galectin-1 expressions in gastric adenocarcinoma and clinicopathologic significance. Pathol Oncol Res. 2010; 16(4):569-77. DOI: 10.1007/s12253-010-9248-8. View

Saussez S, Decaestecker C, Lorfevre F, Cucu D, Mortuaire G, Chevalier D . High level of galectin-1 expression is a negative prognostic predictor of recurrence in laryngeal squamous cell carcinomas. Int J Oncol. 2007; 30(5):1109-17. View

Motran C, Molinder K, Liu S, Poirier F, Miceli M . Galectin-1 functions as a Th2 cytokine that selectively induces Th1 apoptosis and promotes Th2 function. Eur J Immunol. 2008; 38(11):3015-27. PMC: 2782404. DOI: 10.1002/eji.200838295. View

10.

Jung E, Moon H, Cho B, Jeong C, Joo Y, Lee Y . Galectin-1 expression in cancer-associated stromal cells correlates tumor invasiveness and tumor progression in breast cancer. Int J Cancer. 2007; 120(11):2331-8. DOI: 10.1002/ijc.22434. View

11.

Kamper P, Ludvigsen M, Bendix K, Hamilton-Dutoit S, Rabinovich G, Moller M . Proteomic analysis identifies galectin-1 as a predictive biomarker for relapsed/refractory disease in classical Hodgkin lymphoma. Blood. 2011; 117(24):6638-49. DOI: 10.1182/blood-2010-12-327346. View

12.

Danguy A, Camby I, Kiss R . Galectins and cancer. Biochim Biophys Acta. 2002; 1572(2-3):285-93. DOI: 10.1016/s0304-4165(02)00315-x. View

13.

Saussez S, Cucu D, Decaestecker C, Chevalier D, Kaltner H, Andre S . Galectin 7 (p53-induced gene 1): a new prognostic predictor of recurrence and survival in stage IV hypopharyngeal cancer. Ann Surg Oncol. 2006; 13(7):999-1009. DOI: 10.1245/ASO.2006.08.033. View

14.

Schreiber R, Old L, Smyth M . Cancer immunoediting: integrating immunity's roles in cancer suppression and promotion. Science. 2011; 331(6024):1565-70. DOI: 10.1126/science.1203486. View

15.

Soldati R, Berger E, Zenclussen A, Jorch G, Lode H, Salatino M . Neuroblastoma triggers an immunoevasive program involving galectin-1-dependent modulation of T cell and dendritic cell compartments. Int J Cancer. 2011; 131(5):1131-41. DOI: 10.1002/ijc.26498. View

16.

Choufani G, Nagy N, Saussez S, Marchant H, Bisschop P, Burchert M . The levels of expression of galectin-1, galectin-3, and the Thomsen-Friedenreich antigen and their binding sites decrease as clinical aggressiveness increases in head and neck cancers. Cancer. 1999; 86(11):2353-63. DOI: 10.1002/(sici)1097-0142(19991201)86:11<2353::aid-cncr25>3.0.co;2-a. View

17.

Gandhi M, Moll G, Smith C, Dua U, Lambley E, Ramuz O . Galectin-1 mediated suppression of Epstein-Barr virus specific T-cell immunity in classic Hodgkin lymphoma. Blood. 2007; 110(4):1326-9. PMC: 1939905. DOI: 10.1182/blood-2007-01-066100. View

18.

Kuo P, Hung J, Huang S, Chou S, Cheng D, Jong Y . Lung cancer-derived galectin-1 mediates dendritic cell anergy through inhibitor of DNA binding 3/IL-10 signaling pathway. J Immunol. 2010; 186(3):1521-30. DOI: 10.4049/jimmunol.1002940. View

19.

Mao L, Hong W, Papadimitrakopoulou V . Focus on head and neck cancer. Cancer Cell. 2004; 5(4):311-6. DOI: 10.1016/s1535-6108(04)00090-x. View

20.

Rabinovich G, Ilarregui J . Conveying glycan information into T-cell homeostatic programs: a challenging role for galectin-1 in inflammatory and tumor microenvironments. Immunol Rev. 2009; 230(1):144-59. DOI: 10.1111/j.1600-065X.2009.00787.x. View